Views Article – Sharenet Wealth

News, North America

Canada’s Trudeau presses Pfizer CEO on vaccine shortage, hints at travel crackdown

(Adds quotes from Trudeau)

By David Ljunggren

OTTAWA, Jan 22 (Reuters) – Prime Minister Justin Trudeau said on Friday that Pfizer had reassured him it would meet Canada’s vaccine order in full by end-March as, with a second COVID wave spreading across the country, he hinted at a clampdown on citizens leaving home.

Pfizer, which is retooling a European manufacturing plant, told Canada on Tuesday it would receive no vaccine next week, promising more pain for provinces already complaining about a shortage of supplies.

Pfizer also said it would cut supplies to the European Union.

Trudeau, under pressure from political opponents to do more to address the shortage, said that, though the coming weeks would be challenging, the company’s Chief Executive Albert Bourla had reassured him it would supply 4 million vaccine doses as scheduled by March 31.

Expressing irritation that Canadians were still taking vacations despite the worsening second wave, Trudeau also indicated Ottawa would bring in measures designed to make it harder and more expensive to travel.

He spoke on Thursday to the premiers of the 10 provinces, some of whom want Ottawa to clamp down on non-essential travel. He reiterated that people should stay home.

“We could be bringing in new measures that significantly impede your ability to return to Canada at any given moment, without warning,” said Trudeau, promising more details in coming days.

Canada, which has so far reported 18,622 coronavirus deaths from a total of 731,450 cases, already requires all arrivals by air to go into self-administered quarantine for 14 days.

Trudeau said one option was to force people to spend the time in hotel rooms they would have to pay for.

(Reporting by David Ljunggren; editing by John Stonestreet)


© 2019 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. "Reuters" and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.